Review · United States
Tirzepatide
Reviewed on
Approval and product status
Mounjaro and Zepbound have different FDA-approved uses
Mounjaro and Zepbound are separate approved products. Their study results and labels do not apply to every compounded or research-labeled tirzepatide product.
What was measured in people?
- Health results · Strong
- Large studies support blood-sugar and weight findings in the groups studied. FDA separately approved a heart-risk use for Mounjaro in certain adults.
- Body changes · Strong
- Studies have described how approved products enter and affect the body in detail.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
Mounjaro's August 2026 label keeps the boxed warning about thyroid C-cell tumors seen in rats. The human risk is unknown. It also reports temporary worsening of diabetes-related eye disease when blood sugar improves quickly. Other product warnings and precautions still apply. This guide does not recommend a product or give dosing or dose-change instructions.
Still unknown: The evidence does not show that tirzepatide gives everyone the same result. It does not establish a universal “metabolic reset,” longer life, or better athletic performance. Evidence for approved medicines does not make compounded, counterfeit, or research-labeled products equivalent to those medicines.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Products in this review
These are selected records, not every product or form.
Mounjaro
- Ingredients and form
- Injection
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Blood-sugar control in defined type 2 diabetes populations. FDA approved a heart-risk reduction use for certain adults with type 2 diabetes on August 27, 2026.
Published label: August 2026 published label
Read the published Mounjaro FDA label (PDF)Zepbound
- Ingredients and form
- Injection
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Long-term weight management and moderate-to-severe obstructive sleep apnea in defined adults with obesity. An August 26, 2026 FDA supplement added cardiovascular-trial information, not a new use.
Published label: February 2026 published label; August 26, 2026 supplement letter
Read the published Zepbound FDA label (PDF)What the research shows
Mounjaro's August 2026 label covers blood-sugar control in adults and children age 10 or older with type 2 diabetes. It also covers lower risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke in high-risk adults with type 2 diabetes. Cardiovascular death means death from heart or blood-vessel disease.
Zepbound's posted February 2026 label covers long-term weight reduction in defined adults and moderate-to-severe obstructive sleep apnea in adults with obesity. An August 26, 2026, FDA letter added cardiovascular trial information and a warning update. It did not add Mounjaro's heart-risk use to Zepbound.
The studies looked at specific groups of people for set periods. SURPASS-2 studied adults with type 2 diabetes for 40 weeks. SURMOUNT-1 studied adults with obesity, or overweight with a related condition, who did not have diabetes, for 72 weeks. These groups, comparisons, results, and study lengths limit each finding.
Read all Tirzepatide fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 8 sources
- MOUNJARO (tirzepatide) prescribing information, revised August 2026
U.S. Food and Drug Administration · Drug label · 2026
Source accessed
- ZEPBOUND (tirzepatide) prescribing information, revised February 2026
U.S. Food and Drug Administration · Drug label · 2026
Source accessed
- FDA approval letter: Mounjaro heart-risk indication, August 27, 2026
U.S. Food and Drug Administration · FDA review · 2026
Source accessed
- FDA supplement letter: Zepbound cardiovascular-trial information, August 26, 2026
U.S. Food and Drug Administration · FDA review · 2026
Source accessed
- FDA review: tirzepatide's 39-amino-acid structure
U.S. Food and Drug Administration · FDA review · 2022
Source accessed
- Tirzepatide once weekly for the treatment of obesity
PubMed · New England Journal of Medicine · Randomized trial · 2022
Source accessed
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
PubMed · New England Journal of Medicine · Randomized trial · 2021
Source accessed
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed